Metformin Hydrochloride Extended Release Tablets

This product is a hypoglycemic drug that can reduce fasting and postprandial hyperglycemia in patients with type 2 diabetes, and can reduce HbAlc by 1% to 2%. Its mechanism of lowering blood sugar is: 1. Increase the sensitivity of peripheral tissues to insulin and increase insulin-mediated glucose utilization. 2. Increase the utilization of glucose by non-insulin-dependent tissues, such as the brain, blood cells, renal medulla, intestines, skin, etc. 3. Inhibit hepatic gluconeogenesis and reduce hepatic glucose output. 4. Inhibit intestinal wall cells from taking up glucose. Unlike the action of insulin, this product does not promote fat synthesis, has no obvious hypoglycemic effect on normal people, and generally does not cause hypoglycemia when used alone for type 2 diabetes. <b

The main ingredient of this product is metformin hydrochloride, and its chemical name is 1,1-dimethylbiguanide hydrochloride.

This product is white irregular-shaped tablets.

1. It can be used for patients with type 2 diabetes who are not satisfied with diet alone, especially those who are obese, and may also help to reduce weight. 2. It can be effective for patients who have poor response to sulfonylureas. 3. It can be used in combination with sulfonylureas or insulin to improve blood sugar control.

There is no fixed dosage for metformin hydrochloride extended-release tablets, and its effective dosage must be determined by the doctor based on the individual patient's condition, blood sugar, and urine sugar test results. The usual initial dose of metformin hydrochloride extended-release tablets is 0.5g/time, once a day, taken with food at dinner. When the condition cannot be controlled, the dosage can be gradually increased according to the condition, increasing by 0.5g/week, but the maximum daily dose cannot exceed 2.0g. If the control of blood sugar is still unsatisfactory with metformin hydrochloride extended-release tablets 2.0g/time, once a day, you can consider trying metformin hydrochloride extended-release tablets 1.0g/time, twice a day.

Common adverse reactions of this product include nausea, vomiting, diarrhea, and metallic taste in the mouth; sometimes there are weakness, tiredness, weight loss, dizziness, and rash; although the incidence of lactic acidosis is very low, it should be noted, and its main clinical manifestations are vomiting, abdominal pain, hyperventilation, and mental disorders; this product can also reduce the intestinal absorption of vitamin B12, reduce hemoglobin, and produce megaloblastic anemia.

The following conditions are contraindicated: 1. Type 2 diabetes with ketoacidosis, liver and kidney dysfunction (serum creatinine exceeds 1.5mg/dl), pulmonary insufficiency, heart failure, acute myocardial infarction, severe infection and trauma, major surgery, and clinical hypotension and hypoxia. 2. Diabetes with severe chronic complications (such as diabetic nephropathy, diabetic fundus lesions). 3. When undergoing radiographic examination. 4. Alcoholics. 5. Patients with severe heart and lung diseases. 6. Patients with vitamin B12, folic acid and iron deficiency. 7. Patients with poor systemic condition (such as

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Not suitable for pregnant and lactating women. Precautions for the elderly: Use with caution in elderly patients (65 years old), as the dosage should be reduced as renal function is weakened.

1. When used in combination with insulin, the hypoglycemic effect is enhanced, and the dosage should be adjusted. 2. This product can enhance the anticoagulant effect of anticoagulants (such as warfarin, etc.), which may cause bleeding tendency. 3. Cimetidine can increase the bioavailability of this product and reduce the renal clearance rate, so the dosage of this product should be reduced. 4. Furosemide increases the serum and whole blood drug concentrations of metformin, but does not change the renal clearance rate of metformin. 5. Nifedipine can increase the absorption of metformin and increase the excretion in urine, but does not affect Tmax and half-life.

Sealed, stored in a cool and dry place. The validity period is tentatively 24 months

0.5g

24 months.

Hainan Haili Pharmaceutical Co., Ltd.

• Founded in:

  1992-12-30

• Address:

  No. 9 Haili Road, Yonggui Industrial Development Zone, Xiuying District, Haikou City

• Tax NO.:

  9146000020133914XP

• Registered Funds:

  60 million yuan

• Website:

  Log in to view

• Email:

  Log in to view